IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-41678-9.html
   My bibliography  Save this article

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Author

Listed:
  • Kevin Yau

    (University of Toronto
    University of Toronto)

  • Alexandra Kurtesi

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Freda Qi

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Melanie Delgado-Brand

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Tulunay R. Tursun

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Queenie Hu

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Miten Dhruve

    (Michael Garron Hospital)

  • Christopher Kandel

    (Michael Garron Hospital)

  • Omosomi Enilama

    (University of British Columbia)

  • Adeera Levin

    (British Columbia Provincial Renal Agency)

  • Yidi Jiang

    (Centre for Clinical Trial Support, Sunnybrook Research Institute)

  • W. Rod Hardy

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Darren A. Yuen

    (University of Toronto)

  • Jeffrey Perl

    (University of Toronto)

  • Christopher T. Chan

    (University of Toronto)

  • Jerome A. Leis

    (University of Toronto)

  • Matthew J. Oliver

    (University of Toronto
    Ontario Renal Network)

  • Karen Colwill

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health)

  • Anne-Claude Gingras

    (Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health
    University of Toronto)

  • Michelle A. Hladunewich

    (University of Toronto
    Ontario Renal Network)

Abstract

Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant.

Suggested Citation

  • Kevin Yau & Alexandra Kurtesi & Freda Qi & Melanie Delgado-Brand & Tulunay R. Tursun & Queenie Hu & Miten Dhruve & Christopher Kandel & Omosomi Enilama & Adeera Levin & Yidi Jiang & W. Rod Hardy & Dar, 2023. "Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease," Nature Communications, Nature, vol. 14(1), pages 1-8, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41678-9
    DOI: 10.1038/s41467-023-41678-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-41678-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-41678-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41678-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.